These findings indicate that PIs substantially disrupt the cross-talk between HER2 and ERα signaling pathways through mechanisms other than those activated by the therapeutic regimens currently used to treat HER2+/ER+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.